Sfoglia per Autore
EFFICACY OF A IDARUBICIN, ETOPOSIDE AND INTERMEDIATE-DOSE CYTARABINE ARABINOSIDE AS SALVAGE THERAPY IN RELAPSING OR RESISTANT UNFAVORABLE LYMPHOMA
1998-01-01 Brusamolino, E; Passamonti, Francesco; Pagnucco, G; Castagnola, C; Lazzarino, M; Bernasconi, C.
Ex vivo manipulation of hematopoietic stem cells for transplantation: The potential role of amifostine
1999-01-01 Balzarotti, M.; Grisanti, S.; Granzow, K.; Saladini, A.; Sala, A.; Nozza, A.; Molteni, A.; Passamonti, F.; Carlo-Stella, C.; Santoro, A.; Siena, S.
EX VIVO MANIPULATION OF HEMATOPOIETIC STEM CELLS FOR TRANSPLANTATION: THE POTENTIAL ROLE OF AMIFOSTINE.SEMINARS IN ONCOLOGY.
1999-01-01 Balzarotti, M.; Grisanti, S.; Granzow, K.; Saladini, A.; Sala, A.; Nozza, A.; Molteni, A.; Passamonti, Francesco; CARLO STELLA, C.; Santoro, A.; Siena, S.
TREATMENT OF EARLY STAGE HODGKIN’S DISEASE WITH FOUR CYCLES OF ABVD FOLLOWED BY ADJUVANT RADIOTHERAPY: ANALYSIS OF EFFICACY AND LONG TERM TOXICITY
2000-01-01 Brusamolino, E; Lunghi, F; Orlandi, E; Astori, C; Passamonti, Francesco; Barat, C; Pagnucco, G; Baio, A; Lazzarino, M; Bernasconi, C.
EFFICACY OF PIPOBROMAN IN THE TREATMENT OF POLYCYTHEMIA VERA: LONG TERM RESULTS IN 163 PATIENTS
2000-01-01 Passamonti, Francesco; Brusamolino, E; Lazzarino, M; Barat, C; Klersy, C; Orlandi, E; Canevari, A; Castelli, G; Merante, S; Bernasconi, C.
Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia.
2001-01-01 Vassallo, C.; Passamonti, Francesco; Merante, S.; Ardigò, M.; Nolli, G.; Mangiacavalli, S.; Borroni, G.
Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients
2001-01-01 Corso, A; Arcaini, L; Mangiacavalli, S; Astori, C; Orlandi, E; Lorenzi, A; Passamonti, Francesco; Klersy, C; Pascutto, C; Canevari Sciorati, A; Lazzarino, M.
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA
2002-01-01 Bernasconi, P.; Boni, M.; Cavigliano, P. M. .; Calatroni, S.; Brusamolino, E.; Passamonti, Francesco; Pistorio, A.; Giardini, I.; Rocca, B.; Caresana, M.; Lazzarino, M.; Brernasconi, C.
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis
2002-01-01 Passamonti, Francesco; Malabarba, L; Orlandi, E; Pascutto, C; Brusamolino, E; Astori, C; Baratè, C; Canevari, A; Corso, A; Bernasconi, P; Cazzola, M; Lazzarino, M.
Leucemia mieloide cronica e sindromi mieloproliferative croniche
2003-01-01 Brusamolino, E; Passamonti, Francesco
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.
2003-01-01 Passamonti, Francesco; Malabarba, L; Orlandi, E; Baratè, C; Canevari, A; Brusamolino, E; Bonfichi, M; Arcaini, L; Caberlon, S; Pascutto, C; Lazzarino, M.
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN.
2003-01-01 Passamonti, Francesco; Lazzarino, M.
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
2003-01-01 Passamonti, Francesco; Vanelli, L; Malabarba, L; Rumi, E; Pungolino, E; Malcovati, L; Pascutto, C; Morra, E; Lazzarino, M; Cazzola, M.
SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS ARE INDOLENT DISORDERS AT HIGH HEPATITIS C VIRUS SEROPREVALENCE WITH DISTINCT PRESENTING FEATURES BUT SIMILAR MORPHOLOGIC AND PHENOTYPIC PROFILES
2004-01-01 Arcaini, L; Paulli, Marco; Boveri, E; Vallisa, D; Bernuzzi, P; Orlandi, E; Incardona, P; Brusamolino, E; Passamonti, Francesco; Burcheri, S; Schena, C; Pascutto, C; Cavanna, L; Magrini, U; Lazzarino, M.
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.
2004-01-01 Passamonti, Francesco; Rumi, E; Malabarba, L; Arcaini, L; Orlandi, E; Brusamolino, E; Pascutto, C; Cazzola, M; Lazzarino, M.
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders
2004-01-01 Passamonti, Francesco; Pietra, D.; Malabarba, L.; Rumi, E.; Della Porta, M. G.; Malcovati, L.; Bonfichi, M.; Pascutto, C.; Lazzarino, M.; Cazzola, M.
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug
2004-01-01 Passamonti, Francesco; Cazzola, M.
Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles
2004-01-01 Arcaini, L.; Paulli, M.; Boveri, E.; Vallisa, D.; Bernuzzi, P.; Orlandi, E.; Incardona, P.; Brusamolino, E.; Passamonti, Francesco; Burcheri, S.; Schena, C.; Pascutto, C.; Cavanna, L.; Magrini, U.; Lazzarino, M.
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
2004-01-01 Passamonti, Francesco; Rumi, E; Pungolino, E; Malabarba, L; Bertazzoni, P; Valentini, M; Orlandi, E; Arcaini, L; Brusamolino, E; Pascutto, C; Cazzola, M; Morra, E; Lazzarino, M.
Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma.
2004-01-01 Arcaini, L; Orlandi, E; Scotti, M; Brusamolino, E; Passamonti, Francesco; Burcheri, S; Colombo, N; Vanelli, L; Sbalzarini, G; Lazzarino, M.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
EFFICACY OF A IDARUBICIN, ETOPOSIDE AND INTERMEDIATE-DOSE CYTARABINE ARABINOSIDE AS SALVAGE THERAPY IN RELAPSING OR RESISTANT UNFAVORABLE LYMPHOMA | 1-gen-1998 | Brusamolino, E; Passamonti, Francesco; Pagnucco, G; Castagnola, C; Lazzarino, M; Bernasconi, C. | |
Ex vivo manipulation of hematopoietic stem cells for transplantation: The potential role of amifostine | 1-gen-1999 | Balzarotti, M.; Grisanti, S.; Granzow, K.; Saladini, A.; Sala, A.; Nozza, A.; Molteni, A.; Passamonti, F.; Carlo-Stella, C.; Santoro, A.; Siena, S. | |
EX VIVO MANIPULATION OF HEMATOPOIETIC STEM CELLS FOR TRANSPLANTATION: THE POTENTIAL ROLE OF AMIFOSTINE.SEMINARS IN ONCOLOGY. | 1-gen-1999 | Balzarotti, M.; Grisanti, S.; Granzow, K.; Saladini, A.; Sala, A.; Nozza, A.; Molteni, A.; Passamonti, Francesco; CARLO STELLA, C.; Santoro, A.; Siena, S. | |
TREATMENT OF EARLY STAGE HODGKIN’S DISEASE WITH FOUR CYCLES OF ABVD FOLLOWED BY ADJUVANT RADIOTHERAPY: ANALYSIS OF EFFICACY AND LONG TERM TOXICITY | 1-gen-2000 | Brusamolino, E; Lunghi, F; Orlandi, E; Astori, C; Passamonti, Francesco; Barat, C; Pagnucco, G; Baio, A; Lazzarino, M; Bernasconi, C. | |
EFFICACY OF PIPOBROMAN IN THE TREATMENT OF POLYCYTHEMIA VERA: LONG TERM RESULTS IN 163 PATIENTS | 1-gen-2000 | Passamonti, Francesco; Brusamolino, E; Lazzarino, M; Barat, C; Klersy, C; Orlandi, E; Canevari, A; Castelli, G; Merante, S; Bernasconi, C. | |
Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. | 1-gen-2001 | Vassallo, C.; Passamonti, Francesco; Merante, S.; Ardigò, M.; Nolli, G.; Mangiacavalli, S.; Borroni, G. | |
Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients | 1-gen-2001 | Corso, A; Arcaini, L; Mangiacavalli, S; Astori, C; Orlandi, E; Lorenzi, A; Passamonti, Francesco; Klersy, C; Pascutto, C; Canevari Sciorati, A; Lazzarino, M. | |
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA | 1-gen-2002 | Bernasconi, P.; Boni, M.; Cavigliano, P. M. .; Calatroni, S.; Brusamolino, E.; Passamonti, Francesco; Pistorio, A.; Giardini, I.; Rocca, B.; Caresana, M.; Lazzarino, M.; Brernasconi, C. | |
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis | 1-gen-2002 | Passamonti, Francesco; Malabarba, L; Orlandi, E; Pascutto, C; Brusamolino, E; Astori, C; Baratè, C; Canevari, A; Corso, A; Bernasconi, P; Cazzola, M; Lazzarino, M. | |
Leucemia mieloide cronica e sindromi mieloproliferative croniche | 1-gen-2003 | Brusamolino, E; Passamonti, Francesco | |
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. | 1-gen-2003 | Passamonti, Francesco; Malabarba, L; Orlandi, E; Baratè, C; Canevari, A; Brusamolino, E; Bonfichi, M; Arcaini, L; Caberlon, S; Pascutto, C; Lazzarino, M. | |
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN. | 1-gen-2003 | Passamonti, Francesco; Lazzarino, M. | |
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. | 1-gen-2003 | Passamonti, Francesco; Vanelli, L; Malabarba, L; Rumi, E; Pungolino, E; Malcovati, L; Pascutto, C; Morra, E; Lazzarino, M; Cazzola, M. | |
SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS ARE INDOLENT DISORDERS AT HIGH HEPATITIS C VIRUS SEROPREVALENCE WITH DISTINCT PRESENTING FEATURES BUT SIMILAR MORPHOLOGIC AND PHENOTYPIC PROFILES | 1-gen-2004 | Arcaini, L; Paulli, Marco; Boveri, E; Vallisa, D; Bernuzzi, P; Orlandi, E; Incardona, P; Brusamolino, E; Passamonti, Francesco; Burcheri, S; Schena, C; Pascutto, C; Cavanna, L; Magrini, U; Lazzarino, M. | |
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. | 1-gen-2004 | Passamonti, Francesco; Rumi, E; Malabarba, L; Arcaini, L; Orlandi, E; Brusamolino, E; Pascutto, C; Cazzola, M; Lazzarino, M. | |
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders | 1-gen-2004 | Passamonti, Francesco; Pietra, D.; Malabarba, L.; Rumi, E.; Della Porta, M. G.; Malcovati, L.; Bonfichi, M.; Pascutto, C.; Lazzarino, M.; Cazzola, M. | |
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug | 1-gen-2004 | Passamonti, Francesco; Cazzola, M. | |
Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles | 1-gen-2004 | Arcaini, L.; Paulli, M.; Boveri, E.; Vallisa, D.; Bernuzzi, P.; Orlandi, E.; Incardona, P.; Brusamolino, E.; Passamonti, Francesco; Burcheri, S.; Schena, C.; Pascutto, C.; Cavanna, L.; Magrini, U.; Lazzarino, M. | |
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia | 1-gen-2004 | Passamonti, Francesco; Rumi, E; Pungolino, E; Malabarba, L; Bertazzoni, P; Valentini, M; Orlandi, E; Arcaini, L; Brusamolino, E; Pascutto, C; Cazzola, M; Morra, E; Lazzarino, M. | |
Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. | 1-gen-2004 | Arcaini, L; Orlandi, E; Scotti, M; Brusamolino, E; Passamonti, Francesco; Burcheri, S; Colombo, N; Vanelli, L; Sbalzarini, G; Lazzarino, M. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile